VANCOUVER, BC, June 23, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“ MYND“) a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce it has expanded its intellectual property portfolio for diseases of the central nervous system, including methods for treating or delaying Alzheimer’s disease and…


Previous articleCOMPASS Pathways becomes Founding Supporter of the British Neuroscience Association’s inaugural Scholars programme
Next articleBook Review: Alexander Shulgin’s The Nature of Drugs